Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Company News Summary

Starpharma Holdings Announces Positive DEP Phase 2 Interim Results in Prostate Cancer

25 Nov 2021  |  11:13:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Positive DEP phase 2 interim results in prostate cancer

Starpharma Holdings announced positive interim results from its ongoing phase 2 trial of DEP cabazitaxel, showing that 100% (22/22) of evaluable3 patients with hormone refractory, (Stage IV) metastatic prostate cancer. All of these patients have been pre-treated and have had efficacy responses, utilising one or more standard measures of disease. These interim results in prostate cancer show that one or more efficacy signals were observed in 100% of patients assessed following DEP cabazitaxel treatment, and 56% of patients who were evaluable for all three efficacy measures had responses to all three measures.

Please click here for full details

See more ASX300 News Announcements